These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20001460)

  • 21. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
    Harada N; Shimozawa N; Okajima K
    Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.
    Hamada T; Mizuta E; Kondo T; Hirai M; Yamada K; Kato M; Shigemasa C; Yamamoto Y; Ninomiya H; Igawa O; Hisatome I
    Arzneimittelforschung; 2010; 60(2):71-5. PubMed ID: 20329654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan.
    Chrysant SG; Chrysant GS; Desai A
    J Hum Hypertens; 2005 Mar; 19(3):173-83. PubMed ID: 15660122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
    Weber MA; Neutel JM; Smith DH
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S29-35. PubMed ID: 8583478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of enalapril and telmisartan on clinical and biochemical indices of sympathetic activity in hypertensive patients.
    Lewandowski J; Abramczyk P; Dobosiewicz A; Bidiuk J; Sinski M; Gaciong Z
    Clin Exp Hypertens; 2008 Jul; 30(5):423-32. PubMed ID: 18633764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients.
    Fogari R; Mugellini A; Zoppi A; Lazzari P; Destro M; Rinaldi A; Preti P
    J Hum Hypertens; 2006 Mar; 20(3):177-85. PubMed ID: 16306998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
    Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
    Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
    Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension.
    Minami J; Ohno E; Furukata S; Ishimitsu T; Matsuoka H
    J Hum Hypertens; 2009 Oct; 23(10):683-6. PubMed ID: 19369955
    [No Abstract]   [Full Text] [Related]  

  • 36. Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats.
    Kishi T; Hirooka Y; Sunagawa K
    Hypertens Res; 2012 Sep; 35(9):940-6. PubMed ID: 22573203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
    Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
    Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Assessment of antihypertensive effect of telmizartan in patients with hypertensive disease].
    Skavronskaia TV; Fedoseeva LA; Leus AI; Preobrazhenskiĭ DV
    Kardiologiia; 2005; 45(2):56. PubMed ID: 15798709
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic potential of angiotensin receptor blockers in hypertension.
    Cheung BM
    Expert Opin Investig Drugs; 2006 Jun; 15(6):625-35. PubMed ID: 16732715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.